Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants (C-015-404)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Aeras
Sponsor:
Collaborators:
Statens Serum Institut
Sanofi Pasteur, a Sanofi Company
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Information provided by (Responsible Party):
Aeras
ClinicalTrials.gov Identifier:
NCT01861730
First received: May 21, 2013
Last updated: March 14, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)